Page 292 - Drug Class Review
P. 292
Page 176 of 205
Drug Effectiveness Review Project
To evaluate the efficacy and safety of TAC in Chinese patients with probable AD
Parke-Davis Pharmaceutical Division of Warner-Lambert Company
placebo N/A 30 weeks 25 > 50 yrs old; met NINCDS criteria for probable AD with the presence of symptoms for at least 1 year; dementia was mild to moderate as determined by CDR; baseline MMSE score of 10 - 26 Cardiac disease; stroke; diabetes; hepatic or renal insufficiency; any malignancy; prior exposure to TAC; probable VaD with HIS > 4; CT or MRI of a focal brain lesion; evidence of vitamin B 12 deficiency; Concomitant medications except nootropics, anti-depressants, antipsychotics, and sedative-hypnotics; patients taking concomitant medications
Alzheimer Drugs Authors: Wong et al. 67 Year: 1999 Country: Taiwan Study design: RCT Setting: NR Sample size: 100 tacrine 120 mg/d titrated at 30 mg/d 30 weeks 75 hypothyroidism; neurosyphilis
Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
